Coric Vlad 4

What Happened

• Vlad Coric, a director of Veradermics, acquired 58,823 shares twice (total 117,646 shares) in open-market purchases on February 5, 2026 at $17.00 per share, paying $999,991 each time (total cash ~$1,999,982).
• On February 5, 2026, multiple Series A/B/C convertible preferred share holdings automatically converted into common stock on a 10.067-for-1 basis immediately prior to the company’s IPO (no additional consideration). Those conversions resulted in approximately 638,262 common shares being issued to Coric (derivative securities disposed and common stock acquired entries).
• Coric was also reported as acquiring 51,525 shares as a grant/award on February 3, 2026 (recorded at $0.00); this award appears subject to vesting (see footnote F6: fully vested/exercisable on Feb 3, 2027).
• In total, the filing shows Coric acquired roughly 807,433 common shares across the conversions, award and open-market purchases (net of the converted derivative securities).

Key Details

• Dates: Award recorded Feb 3, 2026; conversions and open-market purchases on Feb 5, 2026. Filing date: Feb 5, 2026 (timely).
• Purchase price: $17.00 per share for the two open-market purchases (58,823 shares each); total cash spent ≈ $1,999,982.
• Conversions: Series A/B/C preferred automatically converted 10.067-for-1 into common stock immediately prior to the IPO (no cash paid; no expiration).
• Award/vesting: 51,525-share award noted Feb 3, 2026; footnote F6 says option fully vests/exercisable on Feb 3, 2027.
• Shares held via trusts: some holdings reported as held by Vladimir Coric Family Trust 2013 and Vladimir Coric Marital Trust 2013 (footnotes F2, F3).
• Ownership after transaction: the filing excerpt provided does not state the insider’s total shares outstanding owned following these transactions.

Context

• The open-market purchases are a straightforward cash purchase (bullish signal in that the insider paid market price) totaling about $2.0M. Automatic conversions of preferred into common are a structural change tied to the IPO, not an active buy or sell decision.
• The award is subject to a one-year vesting/exercise schedule per footnote F6; that means those shares are not immediately free of vesting conditions.
• These filings are factual disclosures of insider activity; they do not explain the insider’s motivations.